FDA panel backs wider use of Medtronic's defibrillator
This article was originally published in Clinica
Executive Summary
An FDA advisory panel has recommended that the agency approve Medtronic's Jewel AF implantable cardioverter defibrillator for use in patients who have significant symptoms from atrial fibrillation and for whom anti-arrhythmic drugs have been ineffective. At present, the device's indications are restricted to patients with combined atrial and ventricular fibrillation or who have ventricular fibrillation only.